Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis.

The clinical trial failure dilemma. What constitutes clinical trial failure is a matter of perspective. For sponsors, the ...

In this video interview, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical Trials, talks collaboration and maximizing resources among the various stakeholders in ...

In this video interview, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical Trials, discusses the most prominent challenges he is seeing in the space right now ...

In the Phase III EXPECTS trial, patients experiencing mostly mild posterior circulation ischemic stroke who were ineligible ...

Exploring the different stages in the development of a digital measure, and the activities and steps key to achieving ...

In the Phase III MUSETTE study, a higher dose of intravenous Ocrevus (ocrelizumab) did not provide additional benefit in ...

As oncology research centers scale eSource adoption, the field is shifting toward a fully digital, clinical trial ecosystem.

Why investing in truly effective training from the outset can pay off exponentially for clinical teams—and serve as a ...

These were across five common KRIs (adverse events, serious adverse events, screen failure, early termination, and data entry ...

Since the Orphan Drug Act went into effect in 1983, more than 600 drugs have been approved for rare diseases, according to ...

Research collaboration between Tufts and the Society for Clinical Research Sites explores the prevalence of this belief in ...